Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Frank, Richard T ^a   Edmiston, Marissa ^a   Kendall, Stephen E ^a   Najbauer, Joseph ^a   Cheung, Chia Wei ^a   Kassa, Thewodros ^a   Metz, Marianne Z ^a   Kim, Seung U ^c,d   Glackin, Carlotta A ^a   Wu, Anna M ^b   Yazaki, Paul J ^a   Aboody, Karen S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LENTIVIRUS VECTOR; TRASTUZUMAB; HER2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOMA; CELL DELIVERY SYSTEM; CELL PROLIFERATION; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; PLANT GROWTH; TUMOR CELL; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; CELL MOTION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; METHODOLOGY; NERVE CELL; NUDE MOUSE; PATHOLOGY; SECRETION; STEM CELL; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, NUDE; NEURONS; ORGAN SPECIFICITY; RECEPTOR, ERBB-2; STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949514437     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008314     Document Type: Article

References (22)

1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, et al. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755
2. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, et al. (2006) Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 1: e23.
3. Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15: 739-752
4. Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, et al. (2006) Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncol 8: 119-126
5. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, et al. (2003) Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 14: 1777-1785
6. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, et al. (2007) Tumor- targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 67: 22-25
7. Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, et al. (2008) Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 6: 1819-1829
8. Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA, et al. (2002) Production of immortalized human neural crest stem cells. Methods Mol Biol 198: 55-65
9. Joo KM, Park IH, Shin JY, Jin J, Kang BG, et al. (2009) Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 17: 570-575
10. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, et al. (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67: 4190-4198
11. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, et al. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal anti- body, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749
12. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, et al. (2004) Development of Herceptin resistance in breast cancer cells. Cytometry A 57: 86-93
13. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128
14. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379
15. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59: 1-12
16. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, et al. (1992) Estrogen- dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95
17. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935
18. Melisko ME, Glantz M, Rugo HS (2009) New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 6: 25-33
19. Nielsen DL, Andersson M, Kamby C (2009) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 35: 121-136
20. Spector NL, Blackwell KL (2009) Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2- Positive Breast Cancer. J Clin Oncol.
21. Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, et al. (2004) Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel 17: 481-489
22. Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, et al. (2008) Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26: 1406-1413.